Literature DB >> 10494093

Identification and characterization of hydroxymethylbilane synthase mutations causing acute intermittent porphyria: evidence for an ancestral founder of the common G111R mutation.

A De Siervi1, M V Rossetti, V E Parera, K H Astrin, G I Aizencang, I A Glass, A M Batlle, R J Desnick.   

Abstract

Acute intermittent porphyria (AIP), the most common hepatic porphyria, results from the half-normal activity of hydroxymethylbilane synthase (HMB-synthase; EC 4.3.1.8), the third enzyme in the heme biosynthetic pathway. Because life-threatening acute neurologic attacks of this autosomal dominant disease are triggered by various ecogenic factors (e.g., certain drugs, hormones, alcohol, and starvation), efforts have been directed to identify and counsel presymptomatic heterozygotes in affected families to avoid the precipitating factors. Thus, to determine the nature of the mutations causing AIP in 26 unrelated enzyme-confirmed patients from Argentina, a long-range polymerase chain reaction method was developed to amplify the entire 10-kb gene in two fragments for efficient cycle sequencing and mutation detection. Eight new mutations were identified including two missense mutations (Q34P and G335S), four small deletions (728delCT, 815delAGGA, 948delA, and 985del12), a single base insertion (666insA), and a splice site mutation (IVS12(+1)). In addition, five previously reported mutations (G111R, R173W, Q204X, R201W, and 913insC) were detected. Notably, G111R was identified in 12 of the 26 (46%) presumably unrelated propositi; however, haplotype analysis with intragenic and flanking markers indicated an ancestral founder. Expression of the two new missense mutations (Q34P and G335S) in f1 E. coli resulted in 2.5% or less of the normal expressed enzyme, confirming their defective function. Thus, eight new and five previously reported HMB-synthase mutations, including a common lesion, were detected, permitting accurate identification and counseling of presymptomatic carriers in these 26 unrelated Argentinean AIP families with this dominant porphyria. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10494093

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  9 in total

1.  Identification and expression of mutations in the hydroxymethylbilane synthase gene causing acute intermittent porphyria (AIP).

Authors:  C Solis; I Lopez-Echaniz; D Sefarty-Graneda; K H Astrin; R J Desnick
Journal:  Mol Med       Date:  1999-10       Impact factor: 6.354

2.  Genetic and biochemical characterization of 16 acute intermittent porphyria cases with a high prevalence of the R173W mutation.

Authors:  J To-Figueras; C Badenas; C Carrera; C Muñoz; M Milá; M Lecha; C Herrero
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

3.  Mutation hotspots in the human porphobilinogen deaminase gene: recurrent mutations G111R and R173Q occurring at CpG motifs.

Authors:  X Schneider-Yin; M Hergersberg; M M Schuurmans; A Gregor; E I Minder
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

Review 4.  Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.

Authors:  Makiko Yasuda; Brenden Chen; Robert J Desnick
Journal:  Mol Genet Metab       Date:  2018-11-30       Impact factor: 4.797

5.  Acute intermittent porphyria in Argentina: an update.

Authors:  Gabriela Nora Cerbino; Esther Noemí Gerez; Laura Sabina Varela; Viviana Alicia Melito; Victoria Estela Parera; Alcira Batlle; María Victoria Rossetti
Journal:  Biomed Res Int       Date:  2015-05-17       Impact factor: 3.411

Review 6.  Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators.

Authors:  Helene J Bustad; Juha P Kallio; Marta Vorland; Valeria Fiorentino; Sverre Sandberg; Caroline Schmitt; Aasne K Aarsand; Aurora Martinez
Journal:  Int J Mol Sci       Date:  2021-01-12       Impact factor: 5.923

7.  A novel heterozygous mutation in the HMBS gene in a patient with acute intermittent porphyria and posterior reversible encephalopathy syndrome.

Authors:  Yang Yang; Xiyun Chen; Huijuan Wu; Hua Peng; Wenjing Sun; Bin He; Zhengang Yuan
Journal:  Mol Med Rep       Date:  2020-05-04       Impact factor: 2.952

8.  Molecular Analysis of 55 Spanish Patients with Acute Intermittent Porphyria.

Authors:  María-José Morán-Jiménez; María-José Borrero-Corte; Fátima Jara-Rubio; Inmaculada García-Pastor; Silvia Díaz-Díaz; Francisco-Javier Castelbón-Fernandez; Rafael Enríquez-de-Salamanca; Manuel Méndez
Journal:  Genes (Basel)       Date:  2020-08-12       Impact factor: 4.096

Review 9.  Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution.

Authors:  Miriam Longo; Erika Paolini; Marica Meroni; Paola Dongiovanni
Journal:  Biomedicines       Date:  2022-03-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.